Keros Therapeutics, Inc. Stock Price, News & Analysis

Keros Therapeutics, Inc. (Nasdaq: KROS) reported preliminary topline results from Part 1 of its Phase 1 clinical trial for KER-012, aimed at treating bone-related disorders. The trial involved 32 healthy postmenopausal subjects receiving varying doses of KER-012. Results indicate KER-012 was generally well tolerated up to the highest tested dose of 5 mg/kg, with no serious adverse events reported. Key findings include a 39.6% reduction in follicle-stimulating hormone after a single high dose and significant increases in bone formation markers. Part 2 is ongoing, with data expected in H2 2022.

Keros Therapeutics (Nasdaq: KROS) announced promising results from a preclinical study of RKER-012 for treating pulmonary arterial hypertension (PAH) at the ATS International Conference. RKER-012 effectively prevented increases in pulmonary arterial pressure and right ventricle hypertrophy in a rodent model. In a separate study, KER-012 did not increase red blood cell levels in cynomolgus monkeys. These findings suggest that KER-012 may offer a safer treatment option for PAH without dose-limiting side effects. The company emphasizes KER-012's potential in treating PAH without adversely affecting red blood cell counts.

Keros Therapeutics, Inc. (Nasdaq: KROS) announced the presentation of three abstracts from its KER-050 and ALK2 hematology programs at the 27th Annual Congress of the European Hematology Association (EHA) from June 9-17, 2022. The abstracts include a Phase 2 study on KER-050 for anemia treatment in myelodysplastic syndromes, along with two preclinical studies related to platelet production and anemia of inflammation. KER-050 aims to address low blood cell counts in patients suffering from significant hematological disorders.

Keros Therapeutics (Nasdaq: KROS) reported a net loss of $24.2 million for Q1 2022, up from $15.9 million in Q1 2021, primarily due to increased research and development and infrastructure costs. R&D expenses rose to $18.1 million compared to $11.5 million last year, while G&A expenses increased to $6.0 million from $4.3 million. The company has cash reserves of $228.6 million, expected to sustain operations through Q1 2024. Keros plans to share data from its Phase 2 trial of KER-050 in mid-2022 and initial results from the Phase 1 trial of KER-012 in Q2 2022.

Keros Therapeutics (KROS) reported its fourth quarter and full year 2021 financial results, highlighting a net loss of $6.9 million for Q4 and $58.7 million for the year, up from a $10.7 million loss in Q4 2020. Total revenue for 2021 was $20.1 million, attributed mainly to its strategic partnership with Hansoh for KER-050 in China, which brought in an $18 million upfront payment. Research and development expenses increased significantly to $18.8 million for Q4 as Keros advances clinical trials for KER-050 and KER-012. The company expects its cash reserves to last into Q1 2024.

Keros Therapeutics, Inc. (NASDAQ: KROS) announced that CEO Jasbir S. Seehra, Ph.D. will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 9:20 am ET. The presentation will be available via live webcast and will be archived on Keros’ investors' page for 90 days post-event. Keros specializes in developing treatments for hematological and musculoskeletal disorders, focusing on unmet medical needs with candidates like KER-050 for cytopenias, KER-047 for iron imbalance-related anemia, and KER-012 for bone loss disorders.

Keros Therapeutics, Inc. (KROS) has appointed Christopher Rovaldi as Chief Operating Officer, effective February 1, 2022. Rovaldi brings over 15 years of experience in developing TGF-β molecules across various diseases. His previous roles include senior leadership positions at Acceleron Pharma, and he has been a consultant since 2018. CEO Jasbir S. Seehra emphasized the importance of Rovaldi's expertise in advancing Keros' pipeline of novel treatments for hematological and musculoskeletal disorders. Keros focuses on addressing high unmet medical needs with its lead candidates KER-050, KER-047, and KER-012.

Keros Therapeutics (Nasdaq: KROS) has re-issued a press release from December 13, 2021, to correct typographical errors regarding its Phase 2 clinical trial of KER-050 for treating anemia in patients with myelodysplastic syndromes (MDS). The corrected document states that two cases of treatment-emergent adverse events, nausea and diarrhea, were related to KER-050. The trial aims to assess KER-050's safety and efficacy in various dosing cohorts, with initial data showing promising erythroid responses in evaluable patients. Keros continues to explore KER-050's potential in MDS and related disorders.

Keros Therapeutics, Inc. (KROS) presented additional data from its Phase 2 clinical trial of KER-050 for myelodysplastic syndromes (MDS) at the ASH Annual Meeting on December 13, 2021. The trial evaluates KER-050's efficacy in treating anemia due to MDS, with 50% of evaluable patients achieving an overall erythroid response. Phase 2 results indicate that KER-050 is generally well-tolerated, with no serious adverse events reported. Keros initiated dosing for Cohort 5 at 5.0 mg/kg, continuing to demonstrate promising advancements in hematologic therapies.